Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Inhibition of p38α MAPK rescues cardiomyopathy induced by overexpressed β2-adrenergic receptor, but not β1-adrenergic receptor
Pallavi S. Peter, … , Stephen F. Vatner, Dorothy E. Vatner
Pallavi S. Peter, … , Stephen F. Vatner, Dorothy E. Vatner
Published May 1, 2007
Citation Information: J Clin Invest. 2007;117(5):1335-1343. https://doi.org/10.1172/JCI29576.
View: Text | PDF
Research Article Cardiology

Inhibition of p38α MAPK rescues cardiomyopathy induced by overexpressed β2-adrenergic receptor, but not β1-adrenergic receptor

  • Text
  • PDF
Abstract

We examined the role of p38α MAPK in mediating cardiomyopathy in mice overexpressing β1-adrenergic receptor (β1-AR) or β2-AR by mating them with dominant-negative p38α (DNp38α) MAPK mice. Both β1-AR and β2-AR Tg mice had enhanced LV ejection fraction (LVEF) as young adults and developed similar cardiomyopathy at 11–15 months, characterized by reduced LVEF, myocyte hypertrophy, fibrosis, and apoptosis. We inhibited p38α MAPK by mating β1-AR Tg and β2-AR Tg mice with DNp38α MAPK mice, which rescued the depressed LVEF and reduced apoptosis and fibrosis in bigenic β2-AR × DNp38α MAPK mice, but not bigenic β1-AR × DNp38α MAPK mice, and failed to reduce myocyte hypertrophy in either group. Gsα was increased in both β1-AR Tg and β2-AR Tg mice and was still present in bigenic β1-AR × DNp38α MAPK mice, but not bigenic β2-AR × DNp38α MAPK mice. This suggests that p38α MAPK is one critical downstream signal for the development of cardiomyopathy following chronic β2-AR stimulation, but other kinases may be more important in ameliorating the adverse effects of chronic β1-AR stimulation.

Authors

Pallavi S. Peter, Jennifer E. Brady, Lin Yan, Wei Chen, Stefan Engelhardt, Yibin Wang, Junichi Sadoshima, Stephen F. Vatner, Dorothy E. Vatner

×

Figure 6

Gsα was increased in LVs of both old β1-AR Tg and old β2-AR Tg mice compared with age-matched WT mice, but the increase was greater in β1-AR Tg mice than in β2-AR Tg mice.

Options: View larger image (or click on image) Download as PowerPoint
Gsα was increased in LVs of both old β1-AR Tg and old β2-AR Tg mice comp...
Furthermore, old bigenic β2-AR Tg × DNp38α MAPK mice no longer demonstrated an increase in Gsα, whereas increased Gsα persisted in old bigenic β1-AR Tg × DNp38α MAPK mice. *P < 0.05 versus WT; ‡P < 0.05 versus β1-AR Tg.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts